Navigation Links
BioCryst Presents Phase I Peramivir Data at the Options for the,Control of Influenza Conference

ary 4, 2007 awarded BioCryst a $102.6 million, four-year contract to develop peramivir for the treatment of seasonal and life-threatening influenza. Funding from the contract will support Phase II and Phase III product development activities including manufacturing of clinical lots, process validation, clinical studies and other product approval requirements needed for U.S. licensure. BioCryst retains 100% development and commercialization rights to peramivir worldwide other than in Japan and Korea where BioCryst recently established strategic partnerships with Shionogi & Co. in Japan, and Green Cross in Korea.

About Peramivir

Peramivir is a member of the class of antiviral agents that inhibit influenza viral neuraminidase, an enzyme that is essential for the spread of influenza virus within the host. Peramivir is an inhibitor of influenza A and B neuraminidases and certain strains of influenza viruses that may be resistant to available neuraminidase inhibitors but are susceptible to peramivir in laboratory tests. At the 46th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy in September, 2006, data were presented showing that injectable formulations of peramivir were safely administered to healthy subjects at daily doses up to approximately 600 mg. At the same meeting, animal data were presented showing peramivir promoted survival in animals infected with highly pathogenic strains of the H5N1 virus. Peramivir injection has received Fast Track designation from US FDA and the availability of an intravenous neuraminidase inhibitor may be important in treating patients hospitalized with severe and potentially life-threatening influenza. The availability of an intramuscular formulation of peramivir could ensure appropriate dosing which may be a concern with currently available oral or inhaled anti-influenza agents.

About Influenza

The influenza virus causes an acute viral disease of the respiratory tract. Unlike the
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
3. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
4. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
5. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
6. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
7. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
8. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
9. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
10. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
11. Solstice Neurosciences Presents Escalating Dose Study at International Congress in Istanbul, Turkey
Post Your Comments:
(Date:5/23/2013)... FREDERICK, Md. , May 23, 2013  BioElectronics ... safe consumer medical devices, comments on the FDA panel ... Public Advisory Panel Reclassification – Pulsed Shortwave Therapy Meeting ... Gaithersburg, MD , USA.  The focus of the ... instructed the panel to focus solely on the application ...
(Date:5/23/2013)... 2013 Halozyme Therapeutics, Inc. (NASDAQ: ... David A. Ramsay as ... Vice President, Corporate Development at Halozyme. ... his established financial management experience and his recent ... our commercial group for the last four years, ...
(Date:5/23/2013)... Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ), ... present a company overview at the Deutsche Bank 38 th ... 2013 at 8:40 a.m. ET in Boston, MA. ... presentation will be available on the "Investors & Media" section ... will be available on the Isis Web site within 48 ...
Breaking Medicine Technology:BioElectronics and Pulsed Shortwave Therapy Make Progress 2Halozyme Therapeutics Names David A. Ramsay Chief Financial Officer 2Isis Pharmaceuticals to Present at the Deutsche Bank 38th Annual dbAccess Health Care Conference 2
... Advanced Life Sciences,Holdings, Inc. (Nasdaq: ADLS ... with the National Institute of Allergy and ... biodefense,research, under which the NIAID will conduct ... as a treatment for,anthrax and other high-priority ...
... Compound, AHLi-11, Slated for IND Filing By ... ... Quark Pharmaceuticals, Inc., a,clinical-stage biopharmaceutical company focused on discovering and,developing novel ... the State University of New York at,Buffalo, Center for Hearing & ...
Cached Medicine Technology:Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents 2Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents 3Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents 4Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss 2Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss 3Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss 4
(Date:5/23/2013)... -- Schools should ensure that kids get at ... to support their health and boost performance in ... Although previous studies show 60 minutes of vigorous ... it,s estimated that only about 50 percent of ... to the report from the Institute of Medicine. ...
(Date:5/23/2013)... (HealthDay News) -- Symptoms of borderline personality disorder ... diagnosis and treatment. But researchers in Canada say ... unique to borderline personality disorder: a tendency to ... "They have difficulty processing facial emotions and will ... said Anthony Ruocco, a clinical neuropsychologist and assistant ...
(Date:5/23/2013)... HealthDay Reporter , , THURSDAY, May 23 (HealthDay News) -- ... badly as methamphetamine or crack cocaine, a new study ... mouth, or ,coke mouth, it is startling to see ... the same," said Dr. Mohamed Bassiouny, a professor of ... in Philadelphia. Methamphetamine, crack cocaine and soda -- ...
(Date:5/23/2013)... -- Although a study in 2012 suggested a ... problems associated with Alzheimer,s disease, three groups of ... duplicate those findings. The teams said their ... since the drug involved in the study, bexarotene ... blood-lipid abnormalities, pancreatitis, headaches, fatigue, weight gain, depression, ...
(Date:5/23/2013)... at Emory Vaccine Center have shown that an immune ... responses in mice against viral infections. , The results ... , "Our findings highlight how IL-21 could be important ... Ata Ur Rasheed Mohammed, PhD, the first author of ... director of the Emory Vaccine Center and a Georgia ...
Breaking Medicine News(10 mins):Health News:U.S. School Kids Should Get Hour of Exercise Daily: Report 2Health News:People With Borderline Personality Disorder May Misinterpret Facial Emotions 2Health News:People With Borderline Personality Disorder May Misinterpret Facial Emotions 3Health News:Diet Soda Habit as Bad for Teeth as Meth Addiction, Study Claims 2Health News:Diet Soda Habit as Bad for Teeth as Meth Addiction, Study Claims 3Health News:Scientists Can't Replicate Surprising Finding on Alzheimer's Treatment 2Health News:Vaccine blackjack: IL-21 critical to fight against viral infections 2
... ... has announced that the recent expansion of its production capabilities for various forms of liquid ... ... Inc., a leading custom manufacturer of dietary supplements and homeopathic drugs, has announced that the ...
... research team led by the University of Colorado at ... may provide researchers with a new means of triggering ... The new results are a big step forward ... suicide process that involves a series of biochemical events ...
... COLUMBUS, Ohio Cancer cells in rapidly growing brain ... die. When energy levels are high, tumor cells grow ... less and migrate more., Researchers at the Ohio State ... Richard J. Solove Research Institute have discovered the switch ...
... ... , ... ... ATLANTA , March 11 In recognition of World Kidney Day today, members of the state,s ...
... N.C. , March 11 bioMerieux – a ... diagnostics – today announced the launch of the first Food ... cost-effective solution in the struggle against vancomycin-resistant enterococci (VRE). chromID ... for the qualitative detection of Enterococcus faecium and ...
... Mustache,Mobile Tour is crossing the country from March to September to help celebrate,those special moments that families share around the dinner table. ... and minerals, can help build,stronger families. , ... , ... ...
Cached Medicine News:Health News:GMP Labs Expands Liquid Nutraceutical Capabilities 2Health News:GMP Labs Expands Liquid Nutraceutical Capabilities 3Health News:Discovery of cellular 'switch' may provide new means of triggering cell death, treating disease 2Health News:Discovery of cellular 'switch' may provide new means of triggering cell death, treating disease 3Health News:Researchers discover brain tumor's 'grow-or-go' switch 2Health News:Researchers discover brain tumor's 'grow-or-go' switch 3Health News:Georgia Kidney Community Recognizes World Kidney Day; Echoes Need for Legislation to Improve Access to Dialysis and Transplant Care 2Health News:Georgia Kidney Community Recognizes World Kidney Day; Echoes Need for Legislation to Improve Access to Dialysis and Transplant Care 3Health News:Georgia Kidney Community Recognizes World Kidney Day; Echoes Need for Legislation to Improve Access to Dialysis and Transplant Care 4Health News:bioMerieux Launches Industry-First Vancomycin-Resistant Enterococci (VRE) Screening Tool 2Health News:bioMerieux Launches Industry-First Vancomycin-Resistant Enterococci (VRE) Screening Tool 3Health News:bioMerieux Launches Industry-First Vancomycin-Resistant Enterococci (VRE) Screening Tool 4Health News:bioMerieux Launches Industry-First Vancomycin-Resistant Enterococci (VRE) Screening Tool 5Health News:The Hispanic got milk? Campaign Visited Dallas to Ask How Moms Saborean el Momento! 2Health News:The Hispanic got milk? Campaign Visited Dallas to Ask How Moms Saborean el Momento! 3
... unique thread design is the ultimate anchor ... to pull out, proven delivery, two sutures ... This provides the orthopedic surgeon a superior ... , ,The TwinFix AB anchor was developed ...
The Mitek BioROC EZ fasteners are PLA implants used for soft tissue reattachment to bone. The BioROC EZ uses Radial Osteo Compression (ROC) design for superior fixation strength. The PLA material abs...
... The Sutureless Mitek ConTack Labral ... an L/DL-PLA washer used for soft ... floating washer adjusts to the bony ... contact. The anchor uses Radial Osteo ...
... a fully absorbable soft tissue anchor designed ... dynamic engagement into cancellous bone, its broad ... tip length provide significant resistance to pullout ... material anchor construction provides the benefits of ...
Medicine Products: